The UF Health Cancer Center was well represented at the ASCO Gastrointestinal Cancers Symposium that was held virtually and in-person in San Francisco, Calif., on Jan. 20-22, 2022.
Virtual Highlight: GI ASCO Presentations
Pancreatic Cancer Clinical Updates
Sherise Rogers, M.D., MPH
Colon Cancer Clinical Updates
Jesus Fabregas, M.D., MPH, FACP
Neuroendocrine Tumor Updates
Brian Ramnaraign, M.D.
Hepatobiliary Cancer Clinical Updates
Ilyas Sahin, M.D.
Rectal Cancer Clinical Updates
Thomas George, M.D., FACP
The 2022 Gastrointestinal (GI) Cancers Symposium offers new, innovative findings in GI cancer treatment, research and care. The symposium offers diverse programs for researchers to connect and showcase their achievements:
- Highly interactive sessions with multidisciplinary perspectives based on the latest international research advances.
- Presentation of the newest innovations and implications for optimal patient care.
- Enhanced opportunities for face-to-face networking and collaboration, and on-demand access to meeting materials.
- Solution-focused strategies for the GI cancer care community.
UF Health Cancer Center Presentations at GI ASCO 2022
A phase Ib/II study (IMMCO-1) of atezolizumab plus tivozanib in immunologically cold pancreatic, gallbladder, and biliary cancers. Author: Brian Hemendra Ramnaraign, Ji-Hyun Lee, Azka Ali, Sherise C. Rogers, Jesus C. Fabregas, Ryan M. Thomas, Carmen Joseph Allegra, Ilyas Sahin, David L. DeRemer, Thomas J. George, Jonathan Alexander Chatzkel
Randomized phase II trial of postoperative adjuvant capecitabine and temozolomide versus observation in high-risk pancreatic neuroendocrine tumors: SWOG S2104. Author: Heloisa P. Soares, Katherine A Guthrie, Syed A. Ahmad, Mary Kay Washington, Brian Hemendra Ramnaraign, Nitya Prabhakar Raj, Carole Seigel, Shay Bellasea, E. Gabriela Chiorean, Arvind Dasari, Jonathan R. Strosberg, Cathy Eng, Philip Agop Philip
Phase II/III study of circulating tumor DNA as a predictive biomarker in adjuvant chemotherapy in patients with stage II colon cancer: NRG-GI005 (COBRA). Author: Van K. Morris, Greg Yothers, Scott Kopetz, Samuel A. Jacobs, Peter C. Lucas, Atif Iqbal, Patrick M Boland, Dustin A. Deming, Aaron James Scott, Howard John Lim, Theodore S. Hong, Norman Wolmark, Thomas J. George
Efficacy of SBP-101, a polyamine metabolic inhibitor, administered in combination with gemcitabine and nab-paclitaxel, as a first-line treatment for patients with metastatic pancreatic ductal adenocarcinoma. Author: Nimit Singhal, Darren Sigal, Niall C. Tebbutt, Aram F Hezel, Adnan Nagrial, Sumit Lumba, Thomas J. George, Sheri Lynn Smith, Suzanne Gagnon, Michael T. Cullen, Michael Walker
Phase II study of durvalumab following neoadjuvant chemoRT in operable rectal cancer: NSABP FR-2. Author: Thomas J. George, Greg Yothers, Samuel A. Jacobs, Gene Grant Finley, James Lloyd Wade, Caio Max Sao Pedro Rocha Lima, Jeffrey Scott Rose, Shalu Pahuja, Anuradha Krishnamurthy, John C. Krauss, Melvin Deutsch, Jesus C. Fabregas, James J. Lee, Carmen Joseph Allegra, Norman Wolmark
A phase II, open-label pilot study evaluating the safety and activity of liposomal irinotecan (Nal-IRI) in combination with 5-FU and oxaliplatin (NALIRIFOX) in preoperative treatment of pancreatic adenocarcinoma: NEO-Nal-IRI study. Author: Sherise C. Rogers, Ji-Hyun Lee, Brian Hemendra Ramnaraign, Kathryn Hitchcock, Steven J. Hughes, Anita Ahmed Turk, Karen Bullock Russell, Ahmad El-Far, Ryan M. Thomas, Jesus C. Fabregas, Ilyas Sahin, Carmen Joseph Allegra, David L. DeRemer, Thomas J. George
A phase II randomized therapeutic optimization trial for subjects with refractory metastatic colorectal cancer using circulating tumor DNA (ctDNA): Rapid 1 trial. Author: Sherise C. Rogers, Shu Wang, Ryan Michael Thomas, Brian Hemendra Ramnaraign, Jesus C. Fabregas, Ilyas Sahin, Stephen Staal, Martina Cathryn Murphy, Anna Melissa Singson Murillo, Merry Jennifer Markham, Frederic J. Kaye, Coy D. Heldermon, Dennie V. Jones, Nam H. Dang, Julia Lee Close, Thomas J. George, Carmen Joseph Allegra
NRG-GI004/SWOG-S1610: Colorectal cancer metastatic dMMR immuno-therapy (COMMIT) study—A randomized phase III study of atezolizumab (atezo) monotherapy versus mFOLFOX6/bevacizumab/atezo in the first-line treatment of patients (pts) with deficient DNA mismatch repair (dMMR) or microsatellite instability high (MSI-H) metastatic colorectal cancer (mCRC). Author: Caio Max Sao Pedro Rocha Lima, Greg Yothers, Samuel A. Jacobs, Hanna Kelly Sanoff, Deirdre Jill Cohen, Katherine A Guthrie, Norah Lynn Henry, Patricia A. Ganz, Scott Kopetz, Peter C. Lucas, Charles David Blanke, Norman Wolmark, Howard S. Hochster, Thomas J. George, Michael J. Overman
NRG-GI008: Colon adjuvant chemotherapy based on evaluation of residual disease (CIRCULATE-US). Arvind Dasari, Yan Lin, Scott Kopetz, Samuel A. Jacobs, Peter C. Lucas, Ibrahim Halil Sahin, Dustin A. Deming, Philip Agop Philip, Theodore S. Hong, Norman Wolmark, Greg Yothers, Thomas J. George, Christopher Hanyoung Lieu
Association of multiplex-immunofluorescence (m-IF) and gene expression signature with prognosis and bevacizumab (bev) treatment outcomes in NRG oncology/NSABP C-08: Implications for combining immune checkpoint blockade (ICB) and bev. Katherine L. Pogue-Geile, Marion E Joy, Ying Wang, Rim S Kim, Patrick G Gavin, Debora Fumagalli, Greg Yothers, Carmen Joseph Allegra, Ashok Srinivasan, Melanie Finnigan, Samuel A. Jacobs, Thomas J. George, Jennifer Marie Suga, Judith O. Hopkins, Naoyuki G. Saito, Norman Wolmark, Soonmyung Paik, Peter C. Lucas
Impact of preoperative chemoradiotherapy (CRT) on the rectal tumor microenvironment (TME) and associated patient outcomes. Author: Mohamed E. Salem, Hsih-Te Yang, Wei Sha, James Thomas Symanowski, Alberto Puccini, Jimmy J. Hwang, Kunal C. Kadakia, Laura W. Musselwhite, Edward S. Kim, Thomas J. George, David Foureau